Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome.

Grugni G, Crinò A, Pagani S, Meazza C, Buzi F, De Toni T, Gargantini L, Pilotta A, Pozzan GB, Radetti G, Ragusa L, Salvatoni A, Sartorio A, Bozzola M; Genetic Obesity Study Group, Italian Society of Pediatric Endocrinology and Diabetology..

J Pediatr Endocrinol Metab. 2011;24(7-8):477-81.

PMID:
21932585
2.

Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.

Grugni G, Marzullo P, Ragusa L, Sartorio A, Trifirò G, Liuzzi A, Crinò A; Genetic Obesity Study Group of the Italian Society of Pediatric Endocrinology and Diabetology..

Clin Endocrinol (Oxf). 2006 Oct;65(4):492-9.

PMID:
16984242
3.

Body fat excess and stimulated growth hormone levels in adult patients with Prader-Willi syndrome.

Grugni G, Crinò A, Bertocco P, Marzullo P.

Am J Med Genet A. 2009 Feb 15;149A(4):726-31. doi: 10.1002/ajmg.a.32713.

PMID:
19267411
4.

Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome.

Grugni G, Guzzaloni G, Moro D, Bettio D, De Medici C, Morabito F.

Clin Endocrinol (Oxf). 1998 Jun;48(6):769-75.

PMID:
9713567
5.

Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome.

Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantonio M.

J Pediatr Endocrinol Metab. 1996 May-Jun;9(3):393-400.

PMID:
8887149
6.

Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably.

Lindgren AC, Hagenäs L, Müller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzén EM.

Acta Paediatr. 1998 Jan;87(1):28-31.

PMID:
9510443
7.

GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.

Corrias A, Bellone J, Beccaria L, Bosio L, Trifirò G, Livieri C, Ragusa L, Salvatoni A, Andreo M, Ciampalini P, Tonini G, Crinò A.

J Endocrinol Invest. 2000 Feb;23(2):84-9.

PMID:
10800760
8.

Characterization of pituitary function with emphasis on GH secretion in the chronic fatigue syndrome.

Moorkens G, Berwaerts J, Wynants H, Abs R.

Clin Endocrinol (Oxf). 2000 Jul;53(1):99-106.

PMID:
10931086
9.

The growth hormone-insulin-like growth factor axis in adult patients with Prader Willi syndrome.

Höybye C, Frystyk J, Thorén M.

Growth Horm IGF Res. 2003 Oct;13(5):269-74.

PMID:
12932748
10.

Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

Grugni G, Guzzaloni G, Morabito F.

J Endocrinol Invest. 2001 May;24(5):340-8.

PMID:
11407654
11.

Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls.

Grugni G, Marostica E, Crinò A, Marzullo P, De Nicolao G, Sartorio A.

Clin Endocrinol (Oxf). 2013 Aug;79(2):224-31. doi: 10.1111/cen.12142. Epub 2013 Apr 5.

PMID:
23301953
12.

Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.

Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC.

Clin Endocrinol (Oxf). 2008 Sep;69(3):443-51. doi: 10.1111/j.1365-2265.2008.03228.x. Epub 2008 Mar 18.

PMID:
18363884
13.

The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.

Marostica E, Grugni G, De Nicolao G, Marazzi N, Crinò A, Cappa M, Sartorio A.

Growth Horm IGF Res. 2013 Dec;23(6):261-6. doi: 10.1016/j.ghir.2013.09.004. Epub 2013 Sep 19.

PMID:
24090687
14.

Sleep cycling alternating pattern (CAP) expression is associated with hypersomnia and GH secretory pattern in Prader-Willi syndrome.

Priano L, Grugni G, Miscio G, Guastamacchia G, Toffolet L, Sartorio A, Mauro A.

Sleep Med. 2006 Dec;7(8):627-33. Epub 2006 Oct 4.

PMID:
17023209
15.
17.

Hypothalamic growth hormone-releasing hormone (GHRH) cell number is increased in human illness, but is not reduced in Prader-Willi syndrome or obesity.

Goldstone AP, Unmehopa UA, Swaab DF.

Clin Endocrinol (Oxf). 2003 Jun;58(6):743-55. Erratum in: Clin Endocrinol (Oxf). 2003 Aug;59(2):266.

PMID:
12780752
18.

Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.

Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Christiansen JS, Höybye C.

Endocrine. 2012 Apr;41(2):191-9. doi: 10.1007/s12020-011-9560-4. Epub 2011 Nov 12. Review.

PMID:
22081257
19.

Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.

Alvarez P, Isidro L, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F.

Clin Endocrinol (Oxf). 2002 Apr;56(4):487-92.

PMID:
11966741
20.

Growth hormone induced lipolysis during short- and long-term administration in adult Prader-Willi patients.

Höybye C, Hilding A, Marcus C, Thorén M.

Growth Horm IGF Res. 2005 Dec;15(6):411-5. Epub 2005 Oct 17.

PMID:
16230042

Supplemental Content

Support Center